Drug therapy during labor and delivery, part 2

作者: Gerald G. Briggs , Stephanie R. Wan

DOI: 10.2146/AJHP050265.P2

关键词:

摘要: Purpose. The drug therapy of common conditions and complications during labor delivery the fetal neonatal effects this are examined. Summary. pharmacologic that occur in primarily involves oxytocin prostaglandins for cervical ripening induction systemic regional narcotic analgesics pain. Because most medications used women do not have Food Drug Administration-approved labeling, pharmacists should understand benefits limitations mother. Although augmentation control pain often require therapy, other, less frequent, may labor. therapies these include anti-infective agents to treat maternal infection prevent diseases; antiretrovirals reduce perinatal HIV-1 transmission from mother fetus; corticosteroids lung immaturity; antihypertensives preeclampsia; anticonvulsants eclampsia; antibiotics prolong pregnancy improve outcomes after premature rupture membranes; tocolytics labor; oxytocin, ergot alkaloids, prostaglandin analogues postpartum hemorrhage. usually benign, but significant morbidity mortality involving mother, fetus, newborn ever-present risks. Conclusion. Awareness requiring will allow hospital make knowledgeable decisions about rapid accessibility critical unit.

参考文章(41)
Murphy El, Laros Rk, Combs Ca, Factors associated with hemorrhage in cesarean deliveries. Obstetrics & Gynecology. ,vol. 77, pp. 77- 82 ,(1991)
Murphy El, Laros Rk, Combs Ca, Factors associated with postpartum hemorrhage with vaginal birth. Obstetrics & Gynecology. ,vol. 77, pp. 69- 76 ,(1991)
P J Meis, C G Hatjis, Sinusoidal fetal heart rate pattern associated with butorphanol administration. Obstetrics & Gynecology. ,vol. 67, pp. 377- 380 ,(1986)
IGNATIA B. VAN DEN VEYVER, KENNETH J. MOISE, CHING-NAN OU, ROBERT J. CARPENTER, The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus Obstetrics & Gynecology. ,vol. 82, pp. 500- 503 ,(1993) , 10.1097/00006250-199310000-00005
CHARLES S. LʼHOMMEDIEU, PATRICIA A. HUBER, DEBORAH K. RASCH, Potentiation of magnesium-induced neuromuscular weakness by gentamicin. Critical Care Medicine. ,vol. 11, pp. 55- 56 ,(1983) , 10.1097/00003246-198301000-00015
Mason Barr, Teratogen update: angiotensin-converting enzyme inhibitors. Teratology. ,vol. 50, pp. 399- 409 ,(1994) , 10.1002/TERA.1420500606
Avraham Shotan, Josef Widerhorn, Agneta Hurst, Uri Elkayam, Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use The American Journal of Medicine. ,vol. 96, pp. 451- 456 ,(1994) , 10.1016/0002-9343(94)90172-4
Scott W. Snyder, Michael S. Cardwell, Neuromuscular blockade with magnesium sulfate and nifedipine American Journal of Obstetrics and Gynecology. ,vol. 161, pp. 35- 36 ,(1989) , 10.1016/0002-9378(89)90226-3
Jelena Martinovic, Alexandra Benachi, Nicole Laurent, Farida Daïkha-Dahmane, Marie Claire Gubler, Fetal toxic effects and angiotensin-II-receptor antagonists. The Lancet. ,vol. 358, pp. 241- 242 ,(2001) , 10.1016/S0140-6736(01)05426-5
Catalin S. Buhimschi, Irina A. Buhimschi, Andrew M. Malinow, Carl P. Weiner, Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor American Journal of Obstetrics and Gynecology. ,vol. 187, pp. 235- 238 ,(2002) , 10.1067/MOB.2002.123890